中国肺癌杂志2011，Vol.14Issue(6)：529-533,5.DOI:10.3779/j.issn.1009-3419.2011.06.09
厄洛替尼100mg/天治疗化疗后进展的晚期肺腺癌的临床研究
Role of Erlotinib 100 mg/d in the Treatment of Advanced Adenocarcinoma Lung Cancer Failed to Previous Chemotherapy
施春雷 1韩宝惠 1顾爱琴 1熊丽纹 1沈洁1
作者信息
- 1. 200030,上海,上海交通大学附属胸科医院肺内科
- 折叠
摘要
Abstract
Background and objective Erlotinib is a epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).The standard dose is 150 mg/d.But some patients have to reduce the dose or stop treatment due to its side effects.The aim of this study is to evaluate the efficacy and safety of erlotinib 100 mg on patients with advanced adenocarcinoma lung cancer previously failed to chemotherapy.Methods Forty adenocacinoma patients with histologically confirmed diagnosis were enrolled to be given erlotinib lOO mg/d until disease progression or occurrence ofintolerable toxicity.Relationships between therapeutic effects of erlotinib, progression-free survival, side effects and the clinical characters were analyzed.Results Among 40 patients, 11 got partial response, 14 had a stable disease and i5 had a progressive disease.The total response rate was 27.5％, and the disease control rate was 62.5％.The median progression-free survival was 5.5 months.Fifteen patients were positive for EGFR mutation according to the result of peripheral blood test.The response rate and disease control rate in 15 EGFR-mutation-positive patients were 33.3％ and 73.3％, respectively, and the PFS was 8.4 months for 15 patients.The patients with ECOG 0-1 had a significant better PFS than those with ECOG 2 (6.1 vs 3.1 months) (P=0.043).The most frequent toxicities of erlotinib were rash and diarrhea which were easily controlled.Conclusion Erlotinib 100 mg is effective and safe in treatment of patients with advanced adenocarcinoma, especially for non-smoking patients, patients with good performance status and EGFR-mutation-positive patients.关键词
肺肿瘤/厄洛替尼/靶向治疗/表皮生长因子受体酪氨酸激酶抑制剂Key words
Lung neoplasms/ Erlotinib/ Target therapy/ EGFR-TKI分类
医药卫生引用本文复制引用
施春雷,韩宝惠,顾爱琴,熊丽纹,沈洁..厄洛替尼100mg/天治疗化疗后进展的晚期肺腺癌的临床研究[J].中国肺癌杂志,2011,14(6):529-533,5.
